Suppression of cytomegalovirus latency mechanisms through regulatory effects of specialized neutrophil granulocytes in recurrent sepsis

Suppression of cytomegalovirus latency mechanisms through regulatory effects of specialized neutrophil granulocytes in recurrent sepsis - CMV-Granulo

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00038682

Enrollment

Registered

2025-12-10

Start date

2026-02-16

Completion date

Unknown

Last updated

2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

B25.9

Interventions

Group 1: Patients who initially improved after sepsis with a SOFA score greater than or equal to 2 but now show signs of a new infection with systemic inflammation in the blood (routine laboratory tes

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Sepsis survived within the last month with SOFA score greater than or equal to 2. - CMV seropositivity (detection of anti-CMV IgG) - Increase in banded granulocytes to greater than or equal to 5% in routine laboratory tests

Exclusion criteria

Exclusion criteria: - Pre-existing drug-induced immunosuppression - Malignant hematological condition - Known infection with human immunodeficiency virus

Design outcomes

Primary

Measure	Time frame
Interferon-gamma-release in vitro (yes/no)	—

Secondary

Measure	Time frame
Reactivation intensity (CMV DNA copy number), need for lung replacement therapy (ECMO) (yes/no), duration of lung replacement therapy, duration of ventilation, length of stay in intensive care, length of hospital stay (all of the above in days), need for kidney replacement therapy (yes/no), and mortality.	—

Countries

Germany

Contacts

Public ContactNina Vanessa Pirschtat

Universitätsmedizin Essen

ninavanessa.pirschtat@uk-essen.de+49201 723 84419

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Mar 14, 2026